Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Percheron Therapeutics ( (AU:PER) ) has issued an update.
Percheron Therapeutics has announced the final results of its Phase I clinical trial for HMBD-002. The results of this trial are significant for the company’s operations and may influence its positioning in the pharmaceutical industry, although the inherent risks and uncertainties in drug development are acknowledged.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Average Trading Volume: 3,152,884
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.